tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Knight Therapeutics announces approval, launch of MINJUVI in Argentina
PremiumThe FlyKnight Therapeutics announces approval, launch of MINJUVI in Argentina
7d ago
Knight Therapeutics announces relaunch of MYFEMBREE in Canada
Premium
The Fly
Knight Therapeutics announces relaunch of MYFEMBREE in Canada
1M ago
Knight Therapeutics announces relaunch of ORGOVYX in Canada
Premium
The Fly
Knight Therapeutics announces relaunch of ORGOVYX in Canada
1M ago
Knight Therapeutics Achieves Record Revenues Amid Strategic Expansions
PremiumCompany AnnouncementsKnight Therapeutics Achieves Record Revenues Amid Strategic Expansions
3M ago
Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year
Premium
The Fly
Knight Therapeutics reports Q2 EPS (C$0.13) vs. (C$0.02) last year
3M ago
Knight Therapeutics sees FY25 revenue C$410M-C$420M
Premium
The Fly
Knight Therapeutics sees FY25 revenue C$410M-C$420M
3M ago
Knight Therapeutics closes $50M revolving credit facility
PremiumThe FlyKnight Therapeutics closes $50M revolving credit facility
5M ago
Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal
Premium
Ratings
Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal
5M ago
Knight Therapeutics’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Knight Therapeutics’ Earnings Call: Growth Amid Challenges
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100